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Abstract
The presence of positive surgical margins (PSMs) after partial nephrectomy has been associated with an
increased risk of disease recurrence, but conclusive evidence is lacking. The aim of this study is to examine the
prognostic role of PSMs in a large retrospective cohort with long-term follow-up. PSMs were associated with
disease recurrence, both local and distant, and decreased progression-free survival. Patients with PSMs
should undergo a more intense follow-up.
Background: The role of positive surgical margins (PSMs) on the recurrence of renal cell carcinoma (RCC) after partial
nephrectomy (PN) is debated, and available evidence lacks long-term data. The aim of this study was to evaluate the
predictive role of PSMs on progression-free survival (PFS) in a large cohort followed for at least 5 years.Methods: This
study was a retrospective analysis of a prospectively compiled single-institution database collecting complete
information on more than 2700 patients who had undergone surgery for renal tumor. The data of all the patients
submitted to PN for RCC and with least 5 years follow-up were extracted. Surgical specimens were examined at the
time of surgery only by 2 expert uro-pathologists. A PSM was deﬁned as the presence of cancer cells at the inked
surface of the specimen. The role of PSMs on survival was estimated by Cox regression models adjusted for inﬂuent
covariates. Results: A total of 459 patients fulﬁlled the inclusion criteria and were evaluated. PSMs were observed in
27 (5.9%) cases. No differences in preoperative and pathologic data were found comparing patients with and without
PSMs. At a median follow-up of 96 months (interquartile range, 74-131 months), a clinically evident relapse of RCC
was diagnosed in 36 (7.8%) patients at a median interval of 36 months from PN. Among these, 6 had a PSM for an
incidence of relapse of 22.2% in the PSM group, whereas 30 had negative margins, for an incidence of 6.9%
(P ¼ .013). The sites of relapse were distant organs in 18 cases, and the kidney underwent PN in 21. The patients with
PSMs showed a borderline signiﬁcantly higher incidence of distant metastasis (11.1% vs. 3.5%; P ¼ .071) and a
signiﬁcantly higher incidence of renal relapses (14.8% vs. 3.9%; P ¼ .029). Multivariable Cox models conﬁrmed that
the presence of PSMs was an independent predictor of PFS (odds ratio, 3.127; P ¼ .013). Conclusions: PSMs are an
independent predictor of PFS in patients who underwent PN for RCC, owing to a higher incidence of distant and local
relapses. Surveillance in presence of PSMs should be intensiﬁed and extended for a long time.
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Introduction yearly for an indeﬁnite time. Recurrence was deﬁned by the
Renal cell carcinoma (RCC) represents 2% to 3% of solid
tumors, and its incidence is increasing, especially in young patients.1
According to international guidelines,2,3 partial nephrectomy (PN)
represents the standard of care for organ-conﬁned RCC because it
offers excellent oncologic results4 and better preservation of renal
function5 that could reduce cardiovascular and probably also cancer-
speciﬁc mortality.6-8
Urologists are fairly concerned of the risk of positive surgical
margins (PSMs) because this could jeopardize patients’ survival, as
happens for most oncologic surgeries.9,10 Thus, avoiding a PSM is
paramount, and this goal has been included among all the
composite tools designed to objectivize the outcomes of PN, like
the Trifecta or the Margin Ischemia Complications score.11,12
However, the role of PSMs on the risk of recurrence of RCC is
still under debate because the available evidence is made by
retrospective studies with conﬂicting results. Several authors
reported that a PSM could be relevant on prognosis only for RCC
with pathologic aggressive features,13 but the majority undermined
the potential negative role of PSMs.14 Nevertheless, almost all
these studies provided a relatively short follow-up time that could
have masked the prognostic role of PSMs, especially in case of the
more indolent cancers for which relapses could occur at a very long
distance.15
The aim of this study is to evaluate the oncologic impact of PSMs
in a large single center cohort of patients who underwent PN
followed for at least 5 years.
Materials and Methods
This study was a retrospective review of a prospectively
maintained institutional database including all clinical, surgical,
pathologic, and follow-up data of more than 2700 consecutive
patients who underwent surgery for a renal tumor since 1983. The
indication of radical nephrectomy versus PN followed international
guidelines contemporary to the date of surgery. Operations were
performed through open retroperitoneal, laparoscopic, or robot-
assisted approaches, depending on the period of the study and
surgeon’s preference. After resection, at the discretion of the
surgeon, punch biopsies of the tumor bed were taken and sent for
frozen sections to assess the presence of residual disease and
consistently proceed to wider resection or nephrectomy. According
to institutional policy, the resection strategy for PN intended to
leave a thin layer of healthy parenchyma around the tumor, by
performing an enucleo-resection. Across the period of the study, 2
dedicated expert uro-pathologists (R.T. and S.F.) examined surgical
specimens and deﬁned PSM as the presence of cancer cells at the
inked surface. RCC subtyping was updated to contemporary World
Health Organization classiﬁcation of renal tumors,16 nuclear
grading was attributed according to Fuhrman criteria,17 and path-
ologic staging was assigned according to the Union for International
Cancer Control TNM staging, 2017 edition.18
Patients underwent periodical follow-up controls at a dedicated
outpatient ofﬁce according to a schedule tailored on staging and
grading, as previously reported.19 Brieﬂy, a computed tomography
scan was required at 4 months and then alternated with abdomen
ultrasound plus chest x-rays every 6 months for 2 years, and thenclinical evidence of lesions with features compatible with relapsing
RCC, eventually conﬁrmed at pathologic examination by biopsy
or resection. A local recurrence was intended as the presence of a
new tumor that arose from the previous site of PN identiﬁed
by computed tomography by the hyper-dense plugs or clips
used for the renorrhaphy. Both local recurrences and distant
metastasis were generally candidates for surgical treatment
whenever deemed as technically resectable, otherwise medical
therapy was indicated.
All patients who underwent PN for nonmetastatic RCC with at
least 5 years of follow-up were included in the present analysis. The
prognostic role of the presence of PSMa at ﬁnal pathology was
investigated, accounting for other predictors of progression-free
survival (PFS).
Statistical Analysis
Continuous variables were reported as median and interquartile
range (IQR), and categorical variables as number and proportions.
The Student t test or Mann-Whitney U test were used to compare
continuous variables, and the Pearson c2 test was used for cate-
gorical variables. The endpoint of the study was PFS, deﬁned as the
time between PN and the ﬁrst event of a clinically documented
recurrence or death owing to RCC, censoring the cases with
recurrence. The status of patients who disregarded controls was
updated by consultation of hospital or administrative online regis-
tries or phone calls. Univariate Cox models estimated the association
between predictors, among which PSM was one, and PFS; multi-
variable models assessed the association between PSMs and PFS,
accounting for other inﬂuent covariates selected by univariable
analysis. Differences were considered statistically signiﬁcant with
P  .05, and all P values were 2-sided. Analyses were performed
using SPSS (IBM Corp, IBM SPSS Statistics for Windows, Version
20.0, Armonk, NY).
Results
Over 1055 PNs for a renal tumor were performed after 1983; the
data of 459 patients with ﬁnal pathology consistent with RCC and a
minimum follow-up of 5 years were reviewed. Across the long time
span of the study, the majority of patients were operated on during
the more recent years, as the cumulative incidence of 50% of cases
was reached in 2004. A PSM was found in 27 patients (prevalence
of PSMs, 5.9%), with a higher rate in more recent cases (year of
surgery 1983-2004 vs. 2005-2014, prevalence of PSM 3.8% vs.
8.1%; P ¼ .072). No differences were found in preoperative and
pathologic features according to the status of surgical margins
(Table 1). The cohort was followed for a median time of 96 months
(IQR, 74-131 months) from PN to death or last control. Overall,
39 events of progression were diagnosed in 36 (7.8%) patients, of
whom 6 had a PSM (22% of 27 with PSMs) and 30 a negative
margin (6.9% of 432 with negative margins) (P ¼ .013). The
relapse occurred at distant sites in 18 patients and in the kidney that
previously underwent PN in 21. The incidence of distant metastasis
in patients with PSMs was higher, with borderline statistical
signiﬁcance (3/27 vs. 15/432, or 11.1% vs. 3.5%; P ¼ .071),
whereas the higher incidence of local relapse in the patients withClinical Genitourinary Cancer February 2019 - e27
Table 1 Preoperative and Pathologic Features of Patients
PSMs
27 Patients (5.9%), n (%)
No PSMs
432 Patients (94.1%), n (%) P Value
Gender .982
Male 18 (66.7) 310 (66.9)
Female 9 (33.3) 153 (33.1)
Mean age at surgery, y (SD) 62.2 (10.2) 60.7 (12.7) .719
Mean clinical diameter, cm (SD) 3.2 (1.3) 3.1 (1.3) .832
pT stage .221
pT1a 21 (77.7) 349 (80.8)
pT1b 3 (11.1) 61 (14.1)
pT2 1 (3.8) 6 (1.4)
pT3a 2 (7.4) 16 (3.7)
RCC subtype .361
Clear cell 18 (66.7) 319 (73.8)
Papillary 5 (18.5) 74 (17.1)
Chromophobe 3 (11.1) 28 (6.5)
Others 1 (3.7) 11 (2.6)
Abbreviations: PSMs ¼ Positive surgical margins; RCC ¼ renal cell carcinoma.
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e28 -PSM reached statistical signiﬁcance (4/27 vs. 17/432, or 14.8% vs.
3.9%; P ¼ .029). The median time to distant metastasis was
46 months (IQR, 11-80 months) in the PSM group and 39 months
(IQR, 15-50 months) in other patients (P ¼ .147), whereas the
median time to local recurrence was, respectively, 43 months (IQR,
17-68 months) and 56 months (IQR, 26-96 months) (P ¼ .56).
Multivariable models showed that tumor diameter (odds ratio [OR],
1.269; P < .001), pathologic staging and, in particular, pT3a stage
(OR, 5.734; P < .001), high Fuhrman grading (OR, 5.346;
P ¼ .006), and PSMs (OR, 3.127; P ¼ .013) were independently
predictive of PFS (Table 2).
At the diagnosis of relapse, 23 patients underwent surgical
treatment (16 radical nephrectomies, 7 metastasectomies), 7
patients had medical therapy, and 6 patients received supportive
care. Among the patients who underwent surgery for theTable 2 Univariate and Multivariable Cox Regression Models for Pr
Variable
Univariate
OR (95% CI) P
Tumor diameter, cm 1.340 (1.145-1.567) <.001
Pathologic stage .001
pT1a Referent
pT1b 0.935 (0.325-2.686) .9
pT2 2.114 (0.286-15.621) .47
pT3a 6.213 (2.541-15.193) <.001
High grading 5.399 (1.653-17.632) .005
Histologic subtypea 0.842 (0.557-1.273) .41
Necrosis 1.042 (0.249-4.360) .955
Microvascular invasion 2.005 (0.274-14.666) .493
PSMs 3.608 (1.499-8.683) .004
Abbreviations: CI ¼ Conﬁdence interval; OR ¼ odds ratio; PSMs ¼ positive surgical margins.
aClear-cell renal carcinoma versus other histologic subtypes.
Clinical Genitourinary Cancer February 2019relapse, 10 achieved a long control of the disease, remaining
free from RCC at a median interval of 21 months (IQR, 14-70
months) from recurrence (see Supplemental Table 1 in the online
version).
Discussion
The present study provided an insight on issue of the prognostic
role of PSMs after PN, relying on a cohort with the longest follow-
up reported until now (median time, 8 years). Moreover, the
population has homogeneous features in terms of surgical man-
agement and, most of all, pathologic assessments, because all
patients were treated at 1 institution with only 2 expert uro-
pathologists involved. Within our experience, a PSM was detected
approximately in 6% of PNs for RCC; that is one-half of the range
reported by the literature (0%-15%).20ogression-free Survival After Partial Nephrectomy
Multivariable









Riccardo Tellini et alThe ﬁrst ﬁnding is that the clinical and pathologic features of the
cases with and without PSMs were overlapping, indicating that this
phenomenon is poorly predictable on the basis of the features of the
patient or the tumor, but probably relies on drawbacks of surgical
dissection. Splitting the cohort on 2 periods with the same number
of procedures, before and after 2005, an increase in the incidence of
PSMs was observed, reasonably because of the expansion of the
indications for PN.21 Our data showed an increased risk of recur-
rence of RCC in the presence of PSMs, both at distant sites and,
even more, as relapses in the operated kidney. This involves that the
follow-up schedule after PSMs should include both abdominal and
extra-abdominal— deﬁnitely chest—imaging examinations. In
addition, the higher number of local recurrences after PSMs con-
ﬁrms that a new tumor could grow when malignant cells are left on
the resection bed, as recently shown by a study that reviewed the
pathologic ﬁndings at salvage nephrectomy for a relapse after PN.22
It must therefore be noted that any effort to achieve the complete
removal of the tumor at the time of PN should be done. Of note,
the median time of recurrence in our cohort was approximately 3
years, but occurred within a maximum of 8 years, suggesting that
the follow-up in the case of PSMs might be prolonged. Finally, we
found that in case of recurrences suitable for surgical treatment, a
signiﬁcant number of cases achieved long-term control of the dis-
ease: this corroborates the utility of controls after PN in order to
allow an early diagnosis of recurrence.
The complete removal of the tumor is an obvious primary goal of
oncologic surgery, but differently from other ﬁelds in which PSMs
have a deﬁnite prognostic role and, in turn, speciﬁc manage-
ment23,24; only a little is known about the real harm related to
PSMs after PN. International guidelines often neglect this issue3 or
broadly suggest an “intense surveillance,” without providing further
details.2 The results from existing studies on the prognostic role of
PSMs are conﬂicting. Furthermore, considering that RCC, espe-
cially when poorly aggressive, as in a consistent number of the cases
undergoing PN, could progress at a long distance,15 the majority of
studies are based on a potentially insufﬁcient follow-up time.20
Khalifeh et al,25 in a large retrospective multicenter series of
patients who underwent robot-assisted PN at a median time of 13
months, showed that PSMs were associated with a higher risk of
local recurrence and metastasis with a hazard ratio of 18.4 (P < .01)
and 78.0 (P¼ .02), respectively. Bansal et al,26 in a large population
study with a median follow-up of 15 months, reported that PSMs
were associated with a higher risk of progression. Shah et al13 re-
ported on a multicentric cohort with a median follow-up time of 33
months and concluded that PSMs were predictive of recurrence-free
survival, but only for high-risk tumors (high grading, pT3). Shum
et al,27 in a large matched comparison analysis based on the
National Cancer Database, found a signiﬁcant worse overall survival
in the PSM group (hazard ratio, 1.393; P ¼ .001).
On the other hand, the results from several other studies
undermined the prognostic signiﬁcance of PSMs. In a large multi-
center study28 with a median follow-up time of 37 months, PSMs
were associated with a higher risk of local recurrence but not with
impaired cancer-speciﬁc survival at 5 years. Kang et al,29 in anationwide study on a homogenous cohort of pT1 clear cell RCC,
largely low-grade, followed for a median time of 32 months, re-
ported no differences in PFS.
As highlighted above, there is no consensus on the oncologic
impact of surgical margins. It must be underlined that most studies
are multicentric and therefore suffer from a signiﬁcant bias related to
the variability of margins assessment and lack of central review of
specimens. Second, the longest follow-up times so far reported are
very close to the median value of the latency we observed, having
the advantage of a cohort followed for a signiﬁcantly longer time: it
could be hypothesized that a certain number of events of recurrence
were missed without a prolonged control. Finally, multicentric
studies cannot adequately report data on resection technique that
could inﬂuence the risk of PSMs. Wang et al30 analyzed 117 tumors
removed by simple enucleation or standard PN and found that the
ﬁrst had a higher rate of PSMs (17% vs. 0%). Takagi et al31 instead
reported that the 2 resection techniques lead to similar PSMs. Only
with the diffuse application of a systematic nomenclature, as
suggested by the Surface-Intermediate-Base score,32 a proper
comparison could be done.
Our study has several limitations to be declared, starting from the
retrospective design. The exclusion of the patients still without a
minimal follow-up of 5 years may have led to unexpected selection
biases. Even if only 2 expert uro-pathologists were involved, a slide
review could have added some information, such as the extent of
margin involvement in the case of PSMs. The utility of frozen
sections to protect from PSMs could not have been estimated
because this data was not separately recorded.Conclusion
A PSM is an independent predictor of PFS in patients submitted
to PN for RCC owing to a higher rate of local relapses of disease and
distant metastasis. Until conclusive evidence is able to reveal the best
management of patients with PSMs, a tailored intense and pro-
longed follow-up is mandatory to allow early diagnosis of relapse
and its surgical resection.
Clinical Practice Points
 The role of surgical margin status after PN for RCC is still
debated and no strong conclusions are available.
 In our study, with a long-term follow-up, we managed to
demonstrate the negative prognostic role of PSMs in predicting
disease recurrence.
 These ﬁndings suggest an intense follow-up in patients with
PSMs after conservative surgery for kidney tumors in consider-
ation of the increased risk of disease recurrence.Disclosure
The authors have stated that they have no conﬂicts of interest.
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Supplemental Table 1 Features of Patients With Disease Recurrence After PN for RCC
Patient No. Site of Recurrence
Time to
Recurrence, mo Primary Tumor Features Treatment of Recurrence
1 Operated kidney þ surgical incision 11 ccRCC G3 pT3a Surgery (RN)
2 Operated kidney 23 ccRCC G3 pT1a Surgery (RN)
3 Operated kidney 40 ccRCC G4 pT1a Surgery (RN)
4 Operated kidney 96 pRCC pT1b Surgery (RN)
5 Operated kidney 18 ccRCC G4 pT3a Surgery (RN)
6 Operated kidney 13 ccRCC G3 pT1a Surgery (RN)
7 Operated kidney þ operated renal fossa 37 ccRCC G4 (sarcomatoid features) pT3a Best supportive care
8 Operated kidney 34 ccRCC G2 pT1a Surgery (RN)
9 Operated kidney 42 ccRCC G3 pT1a Surgery (RN)
10 Operated kidney 49 ccRCC G3 pT1a Surgery (RN)
11 Operated kidney þ operated renal fossa 51 ccRCC G3-4 pT1b Surgery (RN)
12 Operated kidney 34 pRCC pT1a Surgery (RN)
13 Operated kidney þ Lung 50 ccRCC G3 pT1b Medical therapy
14 Operated kidney 74 ccRCC G2 pT1a Surgery (RN)
15 Operated kidney 9 ccRCC G3 pT1b Medical therapy
16 Operated kidney 101 chRCC pT1a Surgery (RN)
17 Operated kidney 50 ccRCC G3 pT1a Surgery (partial nephrectomy)
18 Operated kidney 96 ccRCC G2 pT1b Surgery (RN)
19 Operated kidney 52 pRCC pT1a Surgery (RN)
20 Operated kidney 50 ccRCC G2 pT1a Surgery (partial nephrectomy)
21 Operated kidney 116 ccRCC G3 pT1a Surgery (RN)
22 Pancreas 45 ccRCC G3 pT1a Surgery (metastasectomy)
23 Lung 50 pRCC Surgery (metastasectomy)
24 Liver 29 ccRCC G3 pT1b Surgery (metastasectomy)
25 Lung 48 ccRCC G2 pT1a Medical therapy
26 Lung 32 ccRCC G3/4 pT1b Medical therapy
27 Bones 12 ccRCC G4 pT3a Best supportive care
28 Lung 65 ccRCC G3 pT1a Surgery (metastasectomy)
29 Lung 83 pRCC Medical therapy
30 Bones 36 ccRCC G2 pT1a Medical therapy
31 Lung 78 ccRCC G3 pT1b Medical therapy
32 Brain 8 ccRCC G3 pT1a Medical therapy
33 Contralateral adrenal gland 101 ccRCC G2 pT1a Surgery (metastasectomy)
34 Pancreas 35 ccRCC G2 pT1a Surgery (metastasectomy)
35 Bones 10 pRCC G3 pT1b Best supportive care
36 Lung 47 ccRCC G2 pT1a Surgery (metastasectomy)
Abbreviations: ccRCC ¼ Clear-cell renal cell carcinoma; pRCC ¼ papillary renal cell carcinoma; PSM ¼ positive surgical margin; RCC ¼ renal cell carcinoma; RN ¼ radical nephrectomy.
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